and data on titration rates and patients stopping or not adhering to therapy, are still not mature. Nevertheless, Mounjaro arrived on the scene with clinical data showing that it was more ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

"Ozempic is the only version among the weekly injectables — Ozempic, Wegovy, Zepbound and Mounjaro — that has ... go all the way up in the escalation titration dosing of the medication ...